The Filing Desk

Lakefront Biotherapeutics NV vs Novavax

Lakefront Biotherapeutics NV LKFT · Novavax NVAX · Biotechnology

Lakefront Biotherapeutics NV reported revenue of €1.1 billion in fiscal 2025, and Novavax $1.1 billion in fiscal 2025, in different currencies. Lakefront Biotherapeutics NV's revenue grew 303.5% in its latest year, and Novavax's grew 64.7%. Lakefront Biotherapeutics NV had an operating margin of 26.5%, against 40.3% at Novavax. Free cash flow was −€271 million at Lakefront Biotherapeutics NV and −$250 million at Novavax.

Side by side

Lakefront Biotherapeutics NVNovavax
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue€1.1B$1.1B
Revenue growth303.5%64.7%
Revenue growth a year, last 5 years18.4%18.8%
Gross margin97.3%93.5%
Operating margin26.5%40.3%
Net margin28.9%39.2%
Free cash flow−€271M−$250M
Free cash flow margin−24.4%−22.3%
Return on capital——
Net debt to EBITDA—−1.0x
Dividends and buybacks€0M$0M
Change in diluted share count0.0%13.7%
Last close$33.39$7.72
P/E at the last close——
Insider trades, last 12 months——
Piotroski F-score—5 of 9
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
In each company's own currency, fiscal years
Lakefront Biotherapeutics NVNovavax
Operating margin
Percent of revenue
Lakefront Biotherapeutics NVNovavax
Free cash flow
In each company's own currency. Cash from operations minus capital expenditure.
Lakefront Biotherapeutics NVNovavax

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Lakefront Biotherapeutics NV and Novavax pages.